LNTH
Lantheus Holdings, Inc.
A maker of radiopharmaceuticals used to image disease, Lantheus' products include PYLARIFY, an F-18 PET agent that lights up prostate cancer on scans, and DEFINITY, a contrast agent for heart ultrasound. The business began in 1956 as New England Nuclear, founded in Boston, and adopted the coined name "Lantheus" in 2008 when it became an independent company — a made-up brand invented to mark its fresh start.
CUSIP: 516544103HealthcareUS2 holders
Total Value
$8.20M
Total Shares
73.9K
Net Share Change
+30.2K
Activity
2 buying
Investor
Value
Shares
Weight
Change
